Cynthia Moreau

Cynthia Moreau

Auto-generated profile, based on publicly available information

Cynthia Moreau

Ambulatory Pharmacy Services, Baptist Health South Florida, Miami, FL, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2020 in Journal of Pharmacy Practice
Verified
Journal Article
Closed access
PDF file
CMCynthia Moreau
Cynthia Moreau
SMStacey Maravent
Stacey Maravent
GHGenevieve Marie Hale
Genevieve Marie Hale
TJTina Joseph
Tina Joseph
In recent months, the coronavirus pandemic has significantly affected almost every industry in the United States, including health care and higher education. Faculty and students at colleges and schools of pharmacy nationwide have needed to quickly adapt as the delivery of curricula has shifted to primarily online format. Additionally, experiential rotations have been significantly affected as practice settings such as hospitals and outpatient clinics have limited students’ interactions with patients or stopped allowing students on-site altogether. Our commentary will explore strategies that have been employed by experiential education coordinators and pharmacy preceptors from various settings to navigate experiential education during these difficult times while ensuring students successfully meet requirements for graduation. These will include descriptions of transitioning advanced pharmacy practice experiences (APPEs) to virtual format, how to safely involve students in the care of COVID-19 patients, and managing scheduling issues.

1 September 2020 in Clinical Therapeutics
Verified
Journal Article
Closed access
DSDevada Singh-Franco
Devada Singh-Franco
CMCynthia Moreau
Cynthia Moreau
ALAndrea D. Levin
Andrea D. Levin
DRDaisy De La Rosa
Daisy De La Rosa
MJMelinda Johnson
Melinda Johnson

24 June 2020 in Journal of Pharmacy Practice
Verified
Journal Article
Closed access
PDF file
GHGenevieve Marie Hale
Genevieve Marie Hale
CMCynthia Moreau
Cynthia Moreau
TJTina Joseph
Tina Joseph
JPJessica Phyu
Jessica Phyu
NMNemesis Merly
Nemesis Merly
MRMartha M. Rodriguez
Martha M. Rodriguez
Background: As health care moves into the era of value-based medicine, both ambulatory and acute settings are being held accountable for the quality of care provided to patients. Previous studies have shown improved clinical outcomes through medication therapy management (MTM) due to improved medication adherence. Objective: The purpose of this study is to assess the effects of a pharmacist-led MTM clinic in an accountable care organization (ACO) affiliated primary care office on adherence to renin-angiotensin system (RAS) antagonists, diabetic medications, and/or statin medications reported through Healthcare Effectiveness Data and Information Set (HEDIS) Medicare Star Ratings. Methods: In this retrospective cohort study, data were collected via chart review of pharmacist-led MTM patient interviews and follow-ups between October 2015 and April 2017. Eligible patients were Humana HMO Medicare beneficiaries, with at least one chronic disease state, for which they were treated with a RAS antagonist, statin, or diabetic medication. The primary outcome of this investigation was a change in Star Rating scores for medication adherence to RAS antagonists, diabetic medications, and statins from pre- and postpharmacist MTM intervention. Results: A total of 102 patients were referred to the MTM clinic. Out of these, 32 had a follow-up visit, resulting in a total of 25 interventions. One year prior to MTM clinic implementation, most Star Ratings were consistently 3 (out of 5) for RAS antagonists, diabetic medications, and statins. Postintervention, ratings increased to 4 or 5 across these categories. Conclusion: Implementing a pharmacist-led MTM clinic in the ACO primary care setting improves Medicare Star Ratings in patients with chronic conditions.

23 February 2021 in The Journal of the American Board of Family Medicine
Verified
Journal Article
Closed access
PDF file
CMCynthia Moreau
Cynthia Moreau
Pharmacists’ roles and training have evolved to prepare pharmacists to provide clinical patient care services as part of interdisciplinary teams in primary care settings. Especially now, amidst a global health crisis such as COVID-19, patients may become more aware of their health status and be exposed to increased medical information in the media. Additionally, some patients may have delayed routine care, which may result in exacerbations of chronic disease states. Pharmacists can help alleviate the burden on primary care providers by serving as a drug information resource for patients and staff while providing patient education on management of chronic disease states.

11 December 2020 in Journal of Pharmacy Practice
Verified
Journal Article
Closed access
PDF file
TJTina Joseph
Tina Joseph
GHGenevieve Marie Hale
Genevieve Marie Hale
CMCynthia Moreau
Cynthia Moreau
ERElaina D. Rosario
Elaina D. Rosario
NLNichelle Logan
Nichelle Logan
APAlexandra Perez
Alexandra Perez
Background: The Centers for Medicare and Medicaid Services (CMS) publishes quality measures to gauge performance in Accountable Care Organizations (ACOs). ACO-27 (Diabetes Mellitus: Hemoglobin A1c Poor Control) and ACO-41 (Diabetes: Eye Exam), are 2 components for the Diabetes Composite measure. ACO-42 focuses on Statin Therapy for the Prevention and Treatment of Cardiovascular (CV) Disease. There are limited studies regarding the pharmacist role in CV and Diabetes Management in the ACO primary care setting. Objective: To evaluate the impact of pharmacist-led interventions on CV- and diabetes-related CMS quality measures within a primary care-based ACO. Methods: This retrospective pre-post intervention study included 3 primary care-based ACO offices. Patients who met eligibility criteria for CMS quality measures ACO-27, -41 and -42 were included. Pharmacist interventions occurred in December 2018. The study co-primary outcomes were the percentage of patient meeting ACO-27/-41 (composite diabetes-related) and -42 (statin-related) CMS quality measures in the pre-intervention compared to the post-intervention phases. Results: Of 105 patients meeting study inclusion criteria, 77.1% were on statin therapy prior to intervention. After pharmacist intervention, the prevalence of patients on statin therapy increased to 80.0% (p = 0.083). All patients had a HbA1c less than 9% pre-intervention. Sixty-one (58.1%) patients had a documented dilated eye exam prior to intervention. Post-intervention, the prevalence of exams increased to 73.3% (p < 0.0005). Conclusions: Pharmacists can assist primary care providers in the ACO setting meet CV- and diabetes-related CMS quality measures, demonstrating the value of the pharmacist in value-based health care settings.

7 January 2017 in Annals of Pharmacotherapy
Verified
Journal Article
Closed access
CMCynthia Moreau
Cynthia Moreau
KSKaren R. Sando
Karen R. Sando
DZDaniel H. Zambrano
Daniel H. Zambrano
Background: The care of diabetic patients in rural areas is complicated by factors such as poor health literacy, cultural barriers, and primary care provider (PCP) shortages. Integrating pharmacist care in diabetes management in these settings may increase access to care and improve patient outcomes. Objective: To evaluate differences in diabetes-related outcomes in patients with type 2 diabetes (T2DM) managed by a pharmacist diabetes clinic compared with patients only managed by PCPs in a rural family medicine clinic. Methods: This was a retrospective case-control study. The primary outcome was achievement of hemoglobin A 1C (A1C) reduction ≥0.5%. Secondary outcomes included average A1C reduction, achievement of A1C goal, angiotensin-converting enzyme (ACE) inhibitor/angiotensin receptor blocker (ARB) use, statin use, blood pressure control, and frequency of nephropathy screenings. Patients ≥18 years old with an A1C ≥7% were eligible. Cases included patients established with the pharmacist diabetes clinic. Cases were matched to controls in a 1:1 ratio based on PCP, age (±5 years), gender, and race. Results: A total of 21 pharmacist-managed patients met inclusion criteria. Cases were significantly more likely to experience an A1C reduction ≥0.5% (odds ratio = 7.51; 95% CI = 1.54-36.61; P < 0.01). Statistically significant improvements were also noted for ACE inhibitor/ARB use, statin use, and nephropathy screenings among cases. Conclusion: Patients managed by a pharmacist diabetes clinic were more likely to experience improved diabetes-related outcomes, including A1C reduction ≥0.5%. Pharmacist care, when added to standard care, can improve outcomes for patients with T2DM in rural areas.